| Literature DB >> 27004710 |
Emre Aslanger1, Benjamin Assous2, Nicolas Bihry2, Florence Beauvais3, Damien Logeart3, Alain Cohen-Solal3.
Abstract
OBJECTIVE: Functional capacity is one of the cardinal determinants of morbidity and mortality in patients with coronary artery disease (CAD). We hypothesized that baseline cardiovascular mechanics, including cardiac systolic and diastolic functions, arterial mechanics, and ventriculoarterial interaction, may play a role in predicting exercise capacity in patients with CAD.Entities:
Year: 2015 PMID: 27004710 PMCID: PMC5368518 DOI: 10.5152/AnatolJCardiol.2015.6471
Source DB: PubMed Journal: Anatol J Cardiol ISSN: 2149-2263 Impact factor: 1.596
Figure 1Baseline cardiovascular mechanics parameters used in the study. Cardiac parameters were obtained from constructed pressure–volume (PV) loop. Systolic parameters were defined as follows: end-systolic elastance (Ees), which is the slope of the end-systolic PV relationship; V0, which is the zero intercept of Ees; LVEF, left ventricular ejection fraction, which can be deduced from the PV width divided by the PV width plus V0. Diastolic parameters are V15 (volume corresponding to 15 mm Hg on the diastolic PV relationship curve), stiffness constant (estimated from the diastolic PV curve by the equation EDP=α. EDVß), and ventricular compliance (Cvent; ventricular volume divided by diastolic pressure). Arterial parameters were obtained from tonometric measurements. These parameters are follows: arterial compliance (Ca from the diastolic decay curve), arterial elastance (Ea), augmentation pressure (AP; systolic blood pressure minus the pressure at the first peak shoulder of the aortic pulse wave), augmentation index (AIx; AP divided by pulse pressure), and augmentation index at a heart rate of 75 beats per minute (AIx@75). Lastly, ventriculo-arterial coupling is defined as Ees divided by Ea.
Patient characteristics*
| All n=50 | Group I (n=25) | Group II (n=25) | ||
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age, years | 57±10 | 56±10 | 56±10 | 0.61 |
| Male | 44 (88) | 22 (88) | 22 (88) | 1.00 |
| White | 48 (96) | 23 (92) | 25 (100) | 0.49 |
| Hypertension | 39 (58) | 13 (52) | 16 (64) | 0.39 |
| Dyslipidemia | 50 (100) | 25 (100) | 25 (100) | 1.00 |
| Diabetes | 12 (24) | 5 (20) | 7 (28) | 0.74 |
| Tobacco use | 32 (64) | 17 (68) | 15 (60) | 0.55 |
| Prior CABG | 8 (16) | 3 (12) | 5 (20) | 0.70[ |
| Prior MI | 38 (80) | 22 (88) | 18 (72) | 0.28 |
| I | 17 (34) | 7 (28) | 10 (40) | 0.16 |
| II | 19 (38) | 8 (32) | 11 (44) | |
| III | 14 (28) | 10 (40) | 4 (16) | |
| 1-vessel disease | 13 (31) | 7 (30) | 6(33) | 0.98 |
| 2-vessel disease | 14 (34) | 8 (35) | 6 (33) | |
| 3-vessel disease | 14 (34) | 8 (35) | 6 (33) | |
| Weight, kg | 81±15 | 81±13 | 82±16 | 0.81 |
| Height, cm | 172±7 | 172±7 | 172±6 | 0.67 |
| BMI, kg/m2 | 27±4 | 27±3 | 27±5 | 0.90 |
| Systolic blood pressure, mm Hg | 116±19 | 110±15 | 121±20 | 0.04 |
| Diastolic blood pressure, mm Hg | 71±10 | 67±10 | 75±9 | <0.01 |
| Heart rate, beats.min–1 | 64±10 | 66±11 | 62±8 | 0.17 |
| BNP, pg/mL | 234±280 | 373±337 | 101±104 | <0.01 |
| eGFR, mL/min | 91±27 | 81±23 | 101±28 | <0.01 |
| Hb, g/dL | 13±1 | 13±1 | 13±1 | 0.94 |
| ACE-I/ARB | 44 (88) | 24 (96) | 20 (80) | 0.18 |
| Beta-blockers | 45 (90) | 23 (92) | 22 (88) | 1.00 |
| Diuretics | 12 (24) | 9 (36) | 3 (12) | 0.09[ |
| Aldosterone blockers | 14 (28) | 11 (44) | 3 (12) | 0.02[ |
| Statins | 50 (100) | 25 (100) | 25 (100) | 1.00 |
| Digoxin | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| Nitrates | 5 (10) | 1 (4) | 4 (16) | 0.34[ |
Values are presented as mean±standard deviation or n (%). Continuous variables were compared using independent samples t-test. The comparisons of proportions were made using the chi-square test unless stated.
Fischer’s exact test;
P indicates the difference between 2 groups
ACE-I - angiotensin-converting enzyme inhibitors; ARB - angiotensin receptor blocker; BMI - body mass index; BNP - brain-type natriuretic peptide; CABG - coronary artery by-pass grafting; CAD - coronary artery disease; eGFR - estimated glomerular filtration rate (Cockcroft-Gault formula); Hgb - hemoglobin; LVEF - left ventricular ejection fraction; MI - myocardial infarction; NYHA - New York Heart Association
Comparison of CPET variables
| Parameter | All | Group I | Group II | |
|---|---|---|---|---|
| Peak VO2, mL.kg–1.min–1 | 17.9±4.5 | 16.9±4.6 | 18.8±4.3 | 0.14 |
| Percent predicted VO2 | 67±15 | 62±17 | 72±11 | 0.02 |
| πO2, mL O2.kg–1.beat–1 | 12.5±2.9 | 11.7±3.2 | 13.3±2.5 | 0.68 |
| Peak workload, Watts | 103±34 | 96±36 | 109±31 | 0.18 |
| Workload at AT, Watts | 55±26 | 49±24 | 61±27 | 0.11 |
| AT, mL.kg–1.min–1 | 11.2±4.1 | 10.1±3.9 | 12.3±4.0 | 0.05 |
| Percent predicted AT, | 43±17 | 37±16 | 48±16 | 0.02 |
| VE/VCO2 | 35±9 | 39±8 | 31±8 | <0.01 |
AT - anaerobic threshold; Circ Pw - circulatory power; CPET - cardiopulmonary exercise test; VCO2 - the volume of exhaled carbondioxide in a minute; VE - total volume of exhaled air; VO2 - the volume of inhaled oxygen in a minute; πO2 - Oxygen pulse
P indicates the difference between 2 groups, calculated using independent samples t test
Comparison of resting cardiovascular mechanics
| Group I (n=25) | Group II (n=25) | ||
|---|---|---|---|
| LVEF, % | 39±7 | 64±6 | <0.01 |
| Ees, mm Hg.mL–1 | 1.2±0.4 | 1.6±0.6 | <0.01 |
| V0, mL | 6.5±33 | -34±20 | <0.01 |
| V15, mL | 156±57 | 109±23 | <0.01 |
| ß | 6.4±2.4 | 5.8±0.1 | 0.26 |
| Cvent | 0.08±0.04 | 0.09±0.03 | 0.45 |
| E/A ratio | 1.6±1.4 | 1.1±0.5 | 0.11 |
| E/e’ | 11.8±4.8 | 9.3±2.6 | 0.03 |
| Ea, mm Hg.mL–1 | 1.9±0.7 | 1.8±0.5 | 0.60 |
| Ca, mL.mm Hg–1 | 1.9±0.8 | 1.7±0.8 | 0.50 |
| SVR, dyne.s.cm–5 | 1665±664 | 1705±666 | 0.83 |
| AP, mm Hg | 7.6±4.9 | 10.2±6.9 | 0.13 |
| AIx, % | 22±11 | 26±10 | 0.18 |
| AIx@75, % | 18±12 | 21±9 | 0.29 |
| Ees/Ea | 1.6±0.5 | 1.1±0.3 | <0.01 |
Values are mean±standard deviation
P value was calculated using independent samples t-test
AIx - augmentation index; AIx@75 - augmentation index at 75 beats per minute; AP - augmentation pressure; ß - left ventricular stiffness constant; Ca - total arterial compliance; Cvent - left ventricular compliance; E/A - mitral Doppler early to late diastolic velocity ratio; E/e’ - early diastolic mitral Doppler to mitral annular tissue Doppler ratio; Ea - end-systolic arterial elastance; Ees - end-systolic left ventricular elastance; LVEF - left ventricular ejection fraction; SVR - systemic vascular resistance; V0 - zero intercept of the end-systolic pressure–volume relationship; V15 - volume on the diastolic pressure–volume relationship curve corresponding to 15 mm Hg
Figure 2Correlations between the peak VO2 and ventriculo-arterial coupling in patients with abnormal LVEF (<55%) (a) and volume corresponding to 15 mm Hg in the end-diastolic pressure–volume relationship (EDPVRV15) (b) and arterial compliance (c) in patients with normal LVEF (≥55%)
P values were calculated with Pearson’s correlation test